p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements
- 14 June 2001
- journal article
- Published by Springer Nature in Oncogene
- Vol. 20 (27) , 3573-3579
- https://doi.org/10.1038/sj.onc.1204468
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 37 references indexed in Scilit:
- Improving the Detection of p53 Mutations in Breast Cancer by Use of the FASAY, a Functional AssayThe Journal of Molecular Diagnostics, 2000
- Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapyOncogene, 2000
- Prognostic significance ofp53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assayInternational Journal of Cancer, 1999
- Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeastOncogene, 1998
- Heterogeneousp53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonalc-myc andVDJ rearrangementsInternational Journal of Cancer, 1997
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domainsGenes, Chromosomes and Cancer, 1995
- A simple p53 functional assay for screening cell lines, blood, and tumors.Proceedings of the National Academy of Sciences, 1995
- Transcriptional activation by p53 correlates with suppression of growth but not transformationCell, 1994
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994